A5013861508- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Atherosclerosis and Cardiovascular Diseases
- T-cell and B-cell Immunology
- Rheumatoid Arthritis Research and Therapies
- Renal Diseases and Glomerulopathies
- Cytokine Signaling Pathways and Interactions
- Chronic Lymphocytic Leukemia Research
- Systemic Sclerosis and Related Diseases
- Peripheral Neuropathies and Disorders
- Osteoarthritis Treatment and Mechanisms
- Lymphoma Diagnosis and Treatment
- Liver Diseases and Immunity
- Drug-Induced Ocular Toxicity
- Complement system in diseases
- Inflammatory Bowel Disease
- Autoimmune and Inflammatory Disorders Research
- Musculoskeletal synovial abnormalities and treatments
- Pregnancy and Medication Impact
- Autoimmune Bullous Skin Diseases
- Musculoskeletal Disorders and Rehabilitation
- Immune Cell Function and Interaction
- Multiple Sclerosis Research Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
University of California, San Diego
2016-2025
UC San Diego Health System
2018-2024
University of California, Los Angeles
2000-2022
Michigan Medicine
2022
University of California San Diego Medical Center
2021
Center for Rheumatology
1999-2020
University of California System
2019-2020
Gilead Sciences (Germany)
2020
Istanbul University
2016-2019
Spitäler Schaffhausen
2019
The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, incorporate new knowledge regarding immunology SLE.The were derived from a set 702 expert-rated patient scenarios. Recursive partitioning was used derive an initial rule that simplified refined based on SLICC physician...
Oral contraceptives are rarely prescribed for women with systemic lupus erythematosus, because of concern about potential negative side effects. In this double-blind, randomized, noninferiority trial, we prospectively evaluated the effect oral on activity in premenopausal erythematosus.
To test the reliability of Systemic Lupus International Collaborating Clinics/American College Rheumatology (SLICC/ACR) Damage Index and Erythematosus Disease Activity (SLEDAI) in assessment patients with SLE.Ten SLE, representing a spectrum damage activity, were included. Each patient was examined by 6 10 physicians from 5 countries, lupus clinics. The SLICC/ACR used to assess accumulated damage, SLEDAI disease activity. order randomized according Youden square design.The detected...
To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in phase IIb, randomized, double-blind, placebo-controlled study adults with moderate-to-severe systemic lupus erythematosus (SLE).Patients (n = 305) were randomized to receive intravenous anifrolumab (300 mg or 1,000 mg) placebo, addition standard therapy, every 4 weeks for 48 weeks. Randomization was stratified by SLE Disease Activity Index 2000 score (<10 ≥10), oral corticosteroid dosage ≥10...
Background: There is concern that exogenous female hormones may worsen disease activity in women with systemic lupus erythematosus (SLE). Objective: To evaluate the effect of hormone replacement therapy (HRT) on postmenopausal SLE. Design: Randomized, double-blind, placebo-controlled noninferiority trial conducted from March 1996 to June 2002. Setting: 16 university-affiliated rheumatology clinics or practices 11 U.S. states. Patients: 351 menopausal patients (mean age, 50 years) inactive...
Abstract Objective To evaluate treatment with methotrexate (MTX) in patients newly diagnosed giant cell arteritis (GCA) to determine if MTX reduces GCA relapses and cumulative corticosteroid (CS) requirements diminishes disease‐ treatment‐related morbidity. Methods This was a multicenter, randomized, double‐blind study. Over 4 years, 16 centers from the International Network for Study of Systemic Vasculitides enrolled unequivocal GCA. The initial 1 mg/kg/day (≤60 mg every day) prednisone,...
Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE inception cohort. Methods. Patients the Systemic Lupus International Collaborating Clinics cohort (≤15 months of diagnosis) were assessed annually for estimated glomerular filtration rate (eGFR), proteinuria and end-stage renal disease (ESRD). Health-related quality life was measured by Short Form (36 questions) health survey questionnaire (SF-36) subscales, mental physical component summary scores. Results....
<h3>Background and aims</h3> We studied damage accrual factors determining development progression of in an international cohort systemic lupus erythematosus (SLE) patients. <h3>Methods</h3> The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort recruited patients within 15 months developing four or more 1997 American College Rheumatology (ACR) criteria for SLE; the SLICC/ACR index (SDI) was measured annually. assessed relative rates transition using maximum...
Objectives The efficacy and safety of sifalimumab were assessed in a phase IIb, randomised, double-blind, placebo-controlled study ( NCT01283139 ) adults with moderate to severe active systemic lupus erythematosus (SLE). Methods 431 patients randomised received monthly intravenous (200 mg, 600 mg or 1200 mg) placebo addition standard-of-care medications. Patients stratified by disease activity, interferon gene-signature test (high vs low based on the expression four genes) geographical...
Abstract Objective Women with systemic lupus erythematosus (SLE) have a 7–50‐fold increased risk of coronary artery disease (CAD). In the general population, oxidized low‐density lipoprotein (ox‐LDL) increases for CAD. Normal high‐density lipoproteins (HDLs) protect LDL from oxidation; proinflammatory HDLs do not. This study was undertaken to determine whether patients SLE, who chronic inflammation that causes oxidative damage, more HDL and higher levels ox‐LDL, thus predisposing them...
<h3>Objectives</h3> To examine the safety and efficacy of rontalizumab, a humanised IgG1 anti-interferon α (anti-IFN-α) monoclonal antibody, in patients with moderate-to-severe systemic lupus erythematosus (SLE). <h3>Methods</h3> Patients active SLE were randomised (2:1) to 750 mg intravenous rontalizumab every 4 weeks or placebo (Part 1), 300 subcutaneous 2 2). <h3>Background</h3> Hydroxychloroquine corticosteroids allowed. taking immunosuppressants at baseline required per protocol...
To identify a suitable dosing regimen of the CD22-targeted monoclonal antibody epratuzumab in adults with moderately to severely active systemic lupus erythematosus (SLE).A phase IIb, multicentre, randomised controlled study (NCT00624351) was conducted 227 patients (37-39 per arm) receiving either: placebo, 200 mg cumulative dose (cd) (100 every other week (EOW)), 800 cd (400 EOW), 2400 (600 weekly), (1200 or 3600 (1800 EOW). The primary endpoint (not powered for significance) 12 responder...
Objectives To determine the frequency, accrual, attribution and outcome of neuropsychiatric (NP) events impact on quality life over 3 years in a large inception cohort patients with systemic lupus erythematosus (SLE). Methods The study was conducted by Systemic Lupus International Collaborating Clinics. Patients were enrolled within 15 months SLE diagnosis. NP identified using American College Rheumatology case definitions, decision rules derived to proportion disease attributable SLE....
Patients with active rheumatoid arthritis (RA) despite treatment biologic disease-modifying antirheumatic drug (bDMARD) therapy need options.To evaluate the effects of filgotinib vs placebo on signs and symptoms RA in a treatment-refractory population.A 24-week, randomized, placebo-controlled, multinational phase 3 trial conducted from July 2016 to June 2018 at 114 sites internationally, randomizing 449 adult patients (and treating 448) moderately severely inadequate response/intolerance 1...
To evaluate the safety and tolerability of multiple intravenous (IV) doses sifalimumab in adults with moderate-to-severe systemic lupus erythematosus (SLE).In this multicenter, double-blind, placebo-controlled, sequential dose-escalation study, patients were randomized 3:1 to receive IV (0.3, 1.0, 3.0, or 10.0 mg/kg) placebo every 2 weeks week 26, then followed up for 24 weeks. Safety assessment included recording treatment-emergent adverse events (AEs) serious AEs. Pharmacokinetics,...
<h3>Objectives</h3> Evaluate efficacy and safety of tabalumab, a human IgG4 monoclonal antibody that binds neutralises membrane soluble B-cell activating factor (BAFF) versus placebo plus standard care (SoC) in patients with systemic lupus erythematosus (SLE). <h3>Methods</h3> This phase III, 52-week study randomised 1164 moderate-to-severe SLE (Safety Estrogens Lupus Erythematosus National Assessment—SLE Disease Activity Index ≥6 at baseline). Patients received SoC subcutaneous injections...
Objective Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling without substantial reductions in the number of cells. The aim this study was to report results 2 phase III multicenter randomized, double‐blind, placebo‐controlled trials, EMBODY 1 and assessing efficacy safety epratuzumab patients with moderately severely active systemic lupus erythematosus (SLE). Methods Patients met ≥4 American College Rheumatology revised classification criteria for SLE, were...
To explore long-term safety and tolerability of anifrolumab 300 mg compared with placebo in patients systemic lupus erythematosus (SLE) who completed a Treatment Uncontrolled Lupus via the Interferon Pathway (TULIP) trial enrolled placebo-controlled 3-year extension (LTE) study (ClinicalTrials.gov identifier: NCT02794285).
Objectives To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic clinical subgroups. Methods We performed post hoc analyses pooled data from 52-week phase III TULIP-1/TULIP-2 placebo-controlled trials intravenous moderate-to-severe SLE. Outcomes were assessed predefined subgroups: IFNGS (high/low), age, sex, body mass index, race, geographic region, age onset, glucocorticoid use,...
Blood dendritic cell antigen 2 (BDCA2) is a receptor that exclusively expressed on plasmacytoid cells, which are implicated in the pathogenesis of lupus erythematosus. Whether treatment with litifilimab, humanized monoclonal antibody against BDCA2, would be efficacious reducing disease activity patients cutaneous erythematosus has not been extensively studied.In this phase trial, we randomly assigned adults histologically confirmed or without systemic manifestations 1:1:1:1 ratio to receive...
Antibody-binding of blood dendritic cell antigen 2 (BDCA2), which is expressed exclusively on plasmacytoid cells, suppresses the production type I interferon that involved in pathogenesis systemic lupus erythematosus (SLE). The safety and efficacy subcutaneous litifilimab, a humanized monoclonal antibody binds to BDCA2, patients with SLE have not been extensively studied.